MLYS — Mineralys Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1933414 ·
Last close
$29.99
Market Cap
$2.47B
52W High
$31.48
52W Low
$22.42
ADV30
1,147,232
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -45,340,000 | -39,339,000 | 652,862,000 | 112,779,000 | 14,718,000 |
| Dec 2025 | 0 | — | -38,280,000 | -32,234,000 | 661,806,000 | 172,921,000 | 15,113,000 |
| Sep 2025 | 0 | — | -41,131,000 | -36,932,000 | 599,947,000 | 217,597,000 | 23,520,000 |
| Jun 2025 | 0 | — | -46,746,000 | -43,274,000 | 335,724,000 | 101,788,000 | 22,173,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-142,416,000
Investing CF
$-389,753,000
Financing CF
$590,999,000
CapEx
$-37,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-457,169,000
Inventory
—
Receivables
—
ST Investments
$483,714,000
EBIT TTM
$-170,604,000
Pretax Income TTM
$-154,651,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -170,604,000 | -154,651,000 | 661,806,000 | 15,113,000 | — | -142,416,000 |
| Dec 2024 | 0 | -192,403,000 | -177,810,000 | 205,903,000 | 14,646,000 | — | -166,314,000 |
| Dec 2023 | 0 | -84,657,000 | -71,898,000 | 251,636,000 | 10,482,000 | — | -81,173,000 |
| Dec 2022 | 0 | -31,479,000 | -29,799,000 | 114,442,000 | 166,711,000 | — | -29,221,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-85,780,000
OpCashFlow TTM
$0
Assets (Latest)
$205,903,000
Forward EPS
$-1.94
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $2.48B | $21.91 | — |
| VERA | Vera Therapeutics, Inc. | $2.47B | $34.34 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $2.45B | $52.86 | — |
| IDYA | IDEAYA Biosciences, Inc. | $2.58B | $29.35 | — |
| ELVN | Enliven Therapeutics, Inc. | $2.59B | $42.53 | — |
News headlines (Yahoo Finance, 1h cache)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
2026-05-18 20:05 · Yahoo
How FDA NDA Acceptance for Lorundrostat At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story
2026-05-11 15:12 · Yahoo
Mineralys Therapeutics Q1 Earnings Call Highlights
2026-05-07 03:06 · Yahoo
Mineralys Therapeutics, Inc. Q1 2026 Earnings Call Summary
2026-05-07 00:30 · Yahoo
Mineralys (MLYS) Q1 2026 Earnings Transcript
2026-05-06 22:38 · Yahoo
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-06 20:05 · Yahoo
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-05-05 21:34 · Yahoo
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
2026-05-05 12:00 · Yahoo
Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?
2026-05-03 19:46 · Yahoo
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
2026-04-29 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.